Pfizer released a list of programs it stopped developing alongside its second-quarter earnings.
Several obesity-treatment candidates were among them.
One incorporated technology from a Korean company.
3-line summary
1. Pfizer has shelved seven programs since May.
2. One candidate using Oralink is among them.
3. Ending development in Phase 1 is not the same as a technology failure.
Korean technology was among the seven programs
When Pfizer announced its second-quarter earnings on August 4, it also released a pipeline update. It included seven programs whose development had been discontinued since May 5.
One of them was MET-224o, with the development code PF-08656796.
This was an oral GLP-1 obesity-treatment candidate. It used “Oralink,” an oral delivery technology from Korean company D&D Pharmatech, combined with another technology intended to prolong the drug’s effect. As of materials released in May, it had entered Phase 1 clinical trials for the chronic weight-management indication.
D&D Pharmatech said the decision was the result of Pfizer’s portfolio reorganization, not a problem with the technology. It said development of follow-on candidates using Oralink and its collaboration would continue.
After the announcement, the company’s share price fell sharply.
What it means to stop in Phase 1
This is where the weight of the word “discontinued” needs to be assessed precisely.
Developing a new drug involves creating a candidate compound, testing it in animals, and then testing it in people across three phases. Phase 1 clinical trials are the first of those stages. A drug is administered to a small number of people to assess whether it is safe and how it is absorbed and cleared by the body. Whether it works is examined in earnest afterward.
Most pharmaceutical pipeline candidates are eliminated as a matter of course. Only a very small share of candidates that reach early-stage development make it all the way through. That is why large companies advance multiple candidates at once and regularly streamline their lists.
Discontinuing development is not an exceptional event, but an ordinary process in this industry. The reason a program is shelved, however, differs from case to case.
Failure or portfolio cleanup?
This is likely the question readers most want answered, but the publicly available information does not allow a definitive conclusion. There are, however, clues that can help distinguish the two.
How many programs were shelved at once. If only one quietly disappeared, it may be possible that something emerged with that compound. If seven were cleared out together on the same day, the balance shifts toward a company-level judgment rather than an issue with an individual compound.
Whether other candidates using the same technology remain active. If there were a problem with the platform technology itself, it would be natural for other candidates using that technology to be cleared out as well.
Whether the stated reason for discontinuation mentions safety. When development stops because adverse effects emerge in a clinical trial, that fact is usually disclosed separately. In this announcement, Pfizer said it was shifting its focus toward more competitive programs.
Taken together, these three points suggest that this case is better read as the result of Pfizer reshaping its obesity-drug lineup than as a problem with a single compound. The reason Pfizer gave in this announcement was also a strategic shift to concentrate resources on more competitive candidates.
Why oral obesity drugs?
There is a reason this field is so crowded right now.
Most widely used GLP-1 obesity treatments are currently injections. Their efficacy has been established, but their injectable form remains an obstacle. Patients must administer them themselves, they require refrigerated storage, and many people are reluctant to use them.
Turning them into pills would greatly expand the market. The challenge is that GLP-1 is a peptide—a fragment of protein. When swallowed, it is digested in the stomach and intestines. The same thing that happens to protein in food happens to the drug.
That is why a separate delivery technology is needed to solve the problem of how to have it absorbed without being digested. This is what platforms such as Oralink are designed to do.
Several companies are competing in this area, and large companies continually adjust their lists by combining candidates they already have with candidates they acquire. This latest streamlining is one scene in that process.
What to watch
Whether other candidates using Oralink remain in clinical development. A platform’s capabilities become visible not through a single compound, but as results accumulate across multiple cases.
Whether Pfizer has said it will continue pursuing oral GLP-1 drugs. Abandoning an entire class and changing candidates are completely different things.
Clinical results for competitors’ oral obesity drugs. In this field, results from one company can shift the plans of the others as well.
All three can be checked directly without waiting for an article. Pharmaceutical companies’ pipeline pages update their candidate lists each quarter, and clinical-trial status can be checked by searching the compound code at the U.S. clinical trial registry, ClinicalTrials.gov.
Decisions about taking obesity treatments should be discussed with the treating medical professional.
How to read the four characters meaning “discontinued”
One of the seven programs Pfizer shelved used Korean technology, and that compound was in Phase 1 clinical development.
It is common for large companies to streamline early-stage candidates, and the reason the company gave in this announcement was a strategic change, not safety.
When reading the four characters meaning “development discontinued,” looking together at the stage, the number of programs, and the reason development stopped changes how large the event appears.
References
- Kormedi August 5, 2026 report — List of discontinued programs and compound information
- Yaksa Gongron Report on D&D Pharmatech’s position
- Asia Today August 5, 2026 report